NASDAQ:INSY - Insys Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.40 -0.26 (-5.58 %) (As of 01/20/2019 01:49 PM ET)Previous Close$4.40Today's Range$4.2941 - $4.7252-Week Range$3.35 - $11.65Volume724,126 shsAverage Volume490,990 shsMarket Capitalization$326.79 millionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. Receive INSY News and Ratings via Email Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CUSIPN/A Webwww.insysrx.com Phone480-500-3127Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$140.69 million Price / Sales2.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book5.12Profitability EPS (Most Recent Fiscal Year)($0.49) Net Income$-228,010,000.00 Net Margins-128.88% Return on Equity-266.60% Return on Assets-36.62%Miscellaneous Employees343 Outstanding Shares74,270,000Market Cap$326.79 million OptionableOptionable Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions What is Insys Therapeutics' stock symbol? Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY." When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work? Insys Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were distributed to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split. How were Insys Therapeutics' earnings last quarter? Insys Therapeutics Inc (NASDAQ:INSY) announced its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.08. The specialty pharmaceutical company earned $18.30 million during the quarter, compared to analysts' expectations of $24.05 million. Insys Therapeutics had a negative return on equity of 266.60% and a negative net margin of 128.88%. The firm's revenue was down 40.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.30) earnings per share. View Insys Therapeutics' Earnings History. When is Insys Therapeutics' next earnings date? Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Insys Therapeutics. What price target have analysts set for INSY? 5 equities research analysts have issued 12-month target prices for Insys Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Insys Therapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 93.2% from the stock's current price. View Analyst Price Targets for Insys Therapeutics. What is the consensus analysts' recommendation for Insys Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insys Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insys Therapeutics. Has Insys Therapeutics been receiving favorable news coverage? Media headlines about INSY stock have been trending extremely positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insys Therapeutics earned a media sentiment score of 4.1 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. Who are some of Insys Therapeutics' key competitors? Some companies that are related to Insys Therapeutics include Phibro Animal Health (PAHC), Clovis Oncology (CLVS), Wave Life Sciences (WVE), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA) and Alder Biopharmaceuticals (ALDR). Who are Insys Therapeutics' key executives? Insys Therapeutics' management team includes the folowing people: Mr. Saeed Motahari, CEO, Pres & Director (Age 53)Mr. Andrew G. Long, Chief Financial OfficerMr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47)Dr. Danny L. Tuck, Sr. VP of Quality OperationsMr. B. Sanga Emmanuel, VP & Chief Compliance Officer How do I buy shares of Insys Therapeutics? Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Insys Therapeutics' stock price today? One share of INSY stock can currently be purchased for approximately $4.40. How big of a company is Insys Therapeutics? Insys Therapeutics has a market capitalization of $326.79 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe. What is Insys Therapeutics' official website? The official website for Insys Therapeutics is http://www.insysrx.com. How can I contact Insys Therapeutics? Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected] MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 374 (Vote Outperform)Underperform Votes: 284 (Vote Underperform)Total Votes: 658MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: What type of investment options does a Roth IRA provide?